Literature DB >> 16634964

Histological and cytogenetic characterization of bone marrow in relation to prognosis and diagnosis of myelodysplastic syndromes.

Toshiko Sakuma1, Yoshitake Hayashi, Naoki Kanomata, Tohru Murayama, Toshimitsu Matsui, Kazuyoshi Kajimoto, Keisuke Hanioka, Kazuo Chihara, Sakan Maeda.   

Abstract

Bone marrow (BM) histology of 102 myelodysplastic syndromes (MDS) patients was analyzed retrospectively. All the cases were reclassified according to the World Health Organization (WHO) classification. Karyotype study was conducted for all except one. Fifteen of the MDS cases were hypoplastic. The cellularity in bone marrow histology is sometimes ineffective in the differential diagnosis of MDS and aplastic anemia (AA). Nonetheless, a marked decrease in the number of megakaryocytes (average, 0.3/mm(2); range, 0-2/mm(2)) even in the hyperplastic foci of the marrow of AA was the most important histological feature differentiating AA from MDS, whereas the number of megakaryocytes increased in most MDS cases (44/mm(2); range, 1-240/mm(2)) and also in hypoplastic MDS (14/mm(2); range, 8-26/mm(2)). Hyperplastic marrow had a significantly high frequency of progress to acute myeloid leukemia (AML) and hypoplastic MDS had a lower rate of progress to AML. Severe myelofibrosis had a significantly poor prognosis. An increase in CD34-positive cells in MDS indicated a high rate of progress to AML. As for the patients with refractory cytopenia with multilineage dysplasia (RCMD; the new category under the WHO classification), the increased number of megakaryocytes was correlated with poor prognosis.

Entities:  

Mesh:

Year:  2006        PMID: 16634964     DOI: 10.1111/j.1440-1827.2006.01945.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  1 in total

1.  Hemogram and bone marrow morphology in children with chronic aplastic anemia and myelodysplastic syndrome.

Authors:  Jin-Quan Wen; Hai-Lin Feng; Xu-Qing Wang; Ju-Ping Pang
Journal:  World J Pediatr       Date:  2008-02       Impact factor: 2.764

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.